EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

NCT03519984 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Study drug supply issue

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Myelodysplastic/Myeloproliferative Neoplasm
Philadelphia Chromosome Positive
Recurrent Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Secondary Acute Myeloid Leukemia
T Acute Lymphoblastic Leukemia

Interventions

DRUG: Cytarabine
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Recombinant EphB4-HSA Fusion Protein
DRUG: Vincristine Liposomal

Sponsor

University of Southern California

Collaborators

[object Object]
[object Object]
[object Object]